Intrexon Corporation (XON) Shares are Down -10.43%

Intrexon Corporation (XON) has risen sharply, recording gains of 3.12% in the past 4 weeks. However, the stock has corrected -10.43% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 3.34% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 6.55% and the fifty day Moving Average is 0.07%. Intrexon Corporation has dropped 12.99% during the last three month period . Year-to-Date the stock performance stands at -13.37%.

Intrexon Corporation (XON) : Average target price received by Intrexon Corporation (XON) is $43.67 with an expected standard deviation of $12.49. The most aggressive target on the stock is $57, whereas the most downbeat target is $29. 6 financial analysts are currently covering the stock.


Intrexon Corporation (NYSE:XON): stock turned positive on Friday. Though the stock opened at $25.67, the bulls momentum made the stock top out at $26.36 level for the day. The stock recorded a low of $25.35 and closed the trading day at $26.12, in the green by 1.71%. The total traded volume for the day was 1,771,387. The stock had closed at $25.68 in the previous days trading.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.